PMID- 36031727
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221109
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 77
IP  - 10
DP  - 2022 Sep 30
TI  - Faecal carriage of multidrug-resistant bacteria and associated risk factors: 
      results from a point prevalence study.
PG  - 2667-2678
LID - 10.1093/jac/dkac289 [doi]
AB  - OBJECTIVES: Since 2003, incidences of carbapenemase-producing Gram-negative 
      bacilli (CP-GNB) and vancomycin-resistant Enterococcus faecium (VRE) have 
      steadily increased in France. We therefore conducted a point prevalence study to 
      estimate carriage rates of CP-GNB, VRE and ESBL-producing Enterobacterales 
      (ESBL-PE) and associated risk factors. METHODS: Between September 2019 and 
      January 2020, all inpatients hospitalized on a given day in 11 teaching hospitals 
      in the Paris urban area were eligible. Patient interviews and rectal swab 
      screening results were recorded by dedicated nurses. The swabs were plated onto 
      selective chromogenic media and processed using the GeneXpert(R) system. RESULTS: 
      Of 2396 patients, 364 (15.2%) yielded at least one multiresistant bacterial 
      isolate, including 29 CP-GNB carriers (1.2%), 13 VRE carriers (0.5%) and 338 
      ESBL-PE carriers (14%). In 15 patients (4.4% of ESBL-PE carriers and 36.6% of 
      CP-GNB/VRE carriers), concomitant CP-GNB/VRE and ESBL-PE carriage was observed. 
      In 7/29 CP-GNB and 7/13 VRE carriers, carbapenemase production and vanA in the 
      screening samples was only detected with Xpert(R) tests. The OXA-48 gene was 
      predominant in 13/34 CP-GNB isolates from 29 carriers. From the 338 ESBL-PE 
      carriers, 372 isolates were recovered, mainly Escherichia coli (61.2%). Among 379 
      children, 1.1% carried a CP-GNB/VRE strain, and 12.4% carried an ESBL strain. 
      Previous hospitalization outside mainland France, previous antimicrobial 
      treatment and previous ESBL-PE carriage were the main risk factors associated 
      with CP-GNB and/or VRE carriage. CONCLUSIONS: The low CP-GNB and VRE prevalence 
      likely reflects the French policy to limit intrahospital spread of CP-GNB and VRE 
      strains.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of British 
      Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Grohs, Patrick
AU  - Grohs P
AD  - Laboratoire de microbiologie, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Vilfaillot, Aurelie
AU  - Vilfaillot A
AUID- ORCID: 0000-0002-2533-3894
AD  - Unite de Recherche Clinique, Hopital Europeen Georges Pompidou, Paris, France.
AD  - INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France.
FAU - Zahar, Jean Ralph
AU  - Zahar JR
AD  - Equipe Operationnelle en Hygiene, Hopitaux Avicenne, Bobigny/Jean Verdier, 
      Bondy/Rene Muret, Sevran, France.
FAU - Barbut, Frederic
AU  - Barbut F
AD  - Equipe Operationnelle en Hygiene, Hopital St Antoine, Paris, France.
FAU - Frange, Pierre
AU  - Frange P
AUID- ORCID: 0000-0002-4920-8369
AD  - Equipe Operationnelle en Hygiene, Laboratoire de microbiologie clinique, Hopital 
      Necker - Enfants malades, Paris, France.
FAU - Casetta, Anne
AU  - Casetta A
AD  - Equipe Operationnelle en Hygiene, Hopital Cochin, Paris, France.
FAU - Moulin, Veronique
AU  - Moulin V
AD  - Equipe Operationnelle en Hygiene, Hopitaux Corentin Celton/Vaugirard, 
      Issy-les-Moulineaux, France.
FAU - Lawrence, Christine
AU  - Lawrence C
AD  - Equipe Operationnelle en Hygiene, GHU Paris-Saclay site R, Poincare, APHP, 
      Garches, France.
FAU - Baune, Patricia
AU  - Baune P
AD  - Equipe Operationnelle en Hygiene, Hopital Paul Brousse, Villejuif, France.
FAU - Bourgeois, Cleo
AU  - Bourgeois C
AD  - Unite de Recherche Clinique, Hopital Europeen Georges Pompidou, Paris, France.
AD  - INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France.
FAU - Bouffier, Axel
AU  - Bouffier A
AD  - Unite de Recherche Clinique, Hopital Europeen Georges Pompidou, Paris, France.
AD  - INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France.
FAU - Laussucq, Claudine
AU  - Laussucq C
AD  - Laboratoire de microbiologie, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Sienzonit, Lydia
AU  - Sienzonit L
AD  - Laboratoire de microbiologie, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Picard, Simon
AU  - Picard S
AD  - Laboratoire de microbiologie, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Podglajen, Isabelle
AU  - Podglajen I
AD  - Laboratoire de microbiologie, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Kassis-Chikhani, Najiby
AU  - Kassis-Chikhani N
AD  - Equipe Operationnelle en Hygiene, Hopital Europeen Georges Pompidou, Assistance 
      Publique Hopitaux de Paris, Paris, France.
LA  - eng
GR  - AOR 18062/Programme Hospitalier de Recherche Clinique - PHRC 2018/
GR  - Assistance Publique - Hopitaux de Paris/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 6Q205EH1VU (Vancomycin)
RN  - EC 3.5.2.6 (beta-Lactamases)
SB  - IM
MH  - Child
MH  - Drug Resistance, Multiple, Bacterial/genetics
MH  - Gram-Negative Bacteria
MH  - *Gram-Negative Bacterial Infections/microbiology
MH  - Humans
MH  - Prevalence
MH  - Risk Factors
MH  - Vancomycin
MH  - *Vancomycin-Resistant Enterococci
MH  - beta-Lactamases/genetics
EDAT- 2022/08/30 06:00
MHDA- 2022/10/05 06:00
CRDT- 2022/08/29 00:42
PHST- 2022/03/22 00:00 [received]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/08/29 00:42 [entrez]
AID - 6678136 [pii]
AID - 10.1093/jac/dkac289 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2022 Sep 30;77(10):2667-2678. doi: 10.1093/jac/dkac289.